Pfizer/Lilly And J&J Are Readying NGF Inhibitors For Phase III

Pfizer and Lilly plan to resume Phase III testing of their nerve growth factor inhibitor after FDA lifted a partial hold on tanezumab. But J&J is also poised to run new Phase III studies with fulranumab.